GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scinai Immunotherapeutics Ltd (NAS:SCNI) » Definitions » Cash Flow from Investing

Scinai Immunotherapeutics (Scinai Immunotherapeutics) Cash Flow from Investing : $-0.67 Mil (TTM As of Sep. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Scinai Immunotherapeutics Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Sep. 2023, Scinai Immunotherapeutics spent $0.02 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Scinai Immunotherapeutics spent $0.02 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Sep. 2023.


Scinai Immunotherapeutics Cash Flow from Investing Historical Data

The historical data trend for Scinai Immunotherapeutics's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scinai Immunotherapeutics Cash Flow from Investing Chart

Scinai Immunotherapeutics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.23 -2.08 -1.85 -0.14 -0.84

Scinai Immunotherapeutics Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.08 -0.27 -0.01 -0.38 -0.02

Scinai Immunotherapeutics Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Scinai Immunotherapeutics's Cash Flow from Investing for the fiscal year that ended in Dec. 2022 is calculated as:

Scinai Immunotherapeutics's Cash Flow from Investing for the quarter that ended in Sep. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Scinai Immunotherapeutics  (NAS:SCNI) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Scinai Immunotherapeutics's purchase of property, plant, equipment for the three months ended in Sep. 2023 was $-0.02 Mil. It means Scinai Immunotherapeutics spent $0.02 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Scinai Immunotherapeutics's sale of property, plant, equipment for the three months ended in Sep. 2023 was $0.00 Mil. It means Scinai Immunotherapeutics gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Scinai Immunotherapeutics's purchase of business for the three months ended in Sep. 2023 was $0.00 Mil. It means Scinai Immunotherapeutics spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Scinai Immunotherapeutics's sale of business for the three months ended in Sep. 2023 was $0.00 Mil. It means Scinai Immunotherapeutics gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Scinai Immunotherapeutics's purchase of investment for the three months ended in Sep. 2023 was $0.00 Mil. It means Scinai Immunotherapeutics spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Scinai Immunotherapeutics's sale of investment for the three months ended in Sep. 2023 was $0.00 Mil. It means Scinai Immunotherapeutics gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Scinai Immunotherapeutics's net Intangibles purchase and sale for the three months ended in Sep. 2023 was $0.00 Mil. It means Scinai Immunotherapeutics paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Scinai Immunotherapeutics's cash from discontinued investing activities for the three months ended in Sep. 2023 was 0.00 Mil. It means Scinai Immunotherapeutics paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Scinai Immunotherapeutics's cash from other investing activities for the three months ended in Sep. 2023 was $0.00 Mil. It means Scinai Immunotherapeutics paid $0.00 Mil for other investing activities.


Scinai Immunotherapeutics Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Scinai Immunotherapeutics's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Scinai Immunotherapeutics (Scinai Immunotherapeutics) Business Description

Traded in Other Exchanges
Address
Hadassah Ein Kerem Campus, Jerusalem BioPark, 2nd Floor, Jerusalem, ISR
BiondVax Pharmaceuticals Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (NanoAb) pipeline.
Executives
Samuel J Moed director BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCELINE ROAD, LAWRENCEVILLE NJ 08543
Mark Germain director, other: Chairman WELLSFORD REAL PROPERTIES INC, 535 MADISON AVENUE, NEW YORK NY 10022
Uri Ben-or officer: Chief Financial Officer C/O BIOMX LTD., 7 PINHAS SAPIR ST., FLOOR 2, NESS ZIONA L3 7414002
Yael Margolin director 4850 WEST 78TH STREET, INDIANAPOLIS IN 46268
Adi Raviv director STRAUS CAPITAL GROUP, 411 HACKENSACK AVENUE, 7TH FLOOR, HACKENSACK NJ 07601
Morris C Laster director 11 REUVEN SHARI ST., JERUSALEM L3 9724611
Tamar Ben-yedidia officer: Chief Scientist 6 HAZIT ST., MAZKERET BATIA L3 7685421
Avner Rotman director 21 EISENBERG ST., REHOVOT L3 7628905
Amir Reichman director, officer: Chief Executive Officer 269 NAHAL FARAN ST., TAL SHAHAR L3 7680500
Elad Mark officer: Chief Operating Officer 27 HAILANOT, HERZLIYA L3 4631214
George Lowell director 33 DERECH BEIT LECHEM ST., JERUSALEM L3 9355317
Jay Green director 354 CONCESSION 10 E, FREELTON, ON Z4 L8B 1H6

Scinai Immunotherapeutics (Scinai Immunotherapeutics) Headlines